Lifesci Capital Begins Coverage on Immunome (NASDAQ:IMNM)

Lifesci Capital assumed coverage on shares of Immunome (NASDAQ:IMNM) in a report released on Tuesday, MarketBeat.com reports. The firm issued an outperform rating and a $20.00 price objective on the stock. Lifesci Capital also issued estimates for Immunome’s Q1 2025 earnings at ($0.61) EPS, Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.62) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.90) EPS.

A number of other analysts have also weighed in on IMNM. Wedbush restated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research note on Monday. Piper Sandler reduced their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Immunome has a consensus rating of “Buy” and an average target price of $27.17.

Immunome Price Performance

Shares of NASDAQ:IMNM opened at $8.93 on Tuesday. The business has a fifty day moving average price of $10.06 and a 200-day moving average price of $11.87. The company has a market capitalization of $712.41 million, a PE ratio of -1.10 and a beta of 1.93. Immunome has a 1-year low of $8.39 and a 1-year high of $26.70.

Insider Buying and Selling

In other Immunome news, CEO Clay B. Siegall purchased 150,000 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were acquired at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the transaction, the chief executive officer now owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 8.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immunome

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. raised its stake in shares of Immunome by 217.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock worth $6,469,000 after buying an additional 302,916 shares during the period. Victory Capital Management Inc. increased its position in Immunome by 48.1% in the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock worth $10,684,000 after purchasing an additional 237,497 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Immunome by 13.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock valued at $17,657,000 after buying an additional 144,557 shares in the last quarter. Magnus Financial Group LLC lifted its holdings in shares of Immunome by 107.8% in the 4th quarter. Magnus Financial Group LLC now owns 53,536 shares of the company’s stock valued at $569,000 after acquiring an additional 27,777 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its stake in Immunome by 22.2% during the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock worth $6,881,000 after acquiring an additional 85,580 shares during the last quarter. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.